# Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma

> **NCT05367856** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 23 (estimated)

## Conditions studied

- T Cell Lymphoma

## Interventions

- **DRUG:** Chidamide combined with BEAM

## Key facts

- **NCT ID:** NCT05367856
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-28
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05367856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05367856, "Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05367856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*